Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

126 results about "Psychotic illness" patented technology

Psychotic illness. This group of severe illnesses includes schizophrenia and bipolar affective disorder and can affect anyone, regardless of upbringing, social class or personal faith. There are effective treatments in the form of medication and talking therapies.

Long-acting injectable pharmaceutical compositions comprising biodegradable polymers for drug delivery

The present application relates to a sustained release delivery composition of a vesicular monoamine transporter type 2 (VMAT2) inhibitor, a deuterated derivative thereof, a pharmaceutically acceptable salt thereof, an active metabolite thereof, or a prodrug thereof for treatment of hyperkinetic movement disorders including, but not limited to, tardive dyskinesia (TD), Huntington's disease (HD) chorea, tremors, dystonia, chorea, tics, myoclonus, stereotypies, restless legs syndrome, and various other disorders with abnormal involuntary movements. The present application also relates to a sustained release delivery composition of an antipsychotic agent, a pharmaceutically acceptable salt thereof, an active metabolite thereof, or a prodrug thereof for treatment of schizophrenia, bipolar disorder, and other psychiatric diseases or disorders. The method of making or using the composition is also disclosed.
Owner:FORESEE PHARMA CO LTD

Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor

ActiveUS12478623B2Organic active ingredientsOrganic chemistryLumateperoneNeurological problems
The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).
Owner:INTRA CELLULAR THERAPIES INC

Restraining bed for mania psychiatric patient

The invention discloses a mania psychiatric patient restraining bed which comprises a sickbed, a trunk limiting and restraining structure and a leg pressing and fixing device are arranged on the sickbed, the trunk limiting and restraining structure is installed on the sickbed in a clamped mode, and the leg pressing and fixing device is installed on the sickbed in a clamped and sliding mode. The invention belongs to the technical field of psychiatric restraint beds. The invention provides a mania psychiatric patient restraint bed in order to achieve the effects that restraint equipment autonomously limits the movement range of a patient, gradually reduces the movement space of the patient and prevents the patient from struggling to cause injury to other people or himself / herself. The movement range of the upper body is limited, the struggling movement range of the patient is reduced, the movement range of the upper body can be completely limited by matching with the bandage, the movement space of the legs is limited by matching with the pressing automatic tightening structures of the legs, and therefore excessive struggling of the mental patient is avoided.
Owner:AFFILIATDE CANCER HOSPITAL & INST OF GUANGZHOU MEDICAL UNIV

Microbial marker for schizophrenia with social anxiety disorder and prediction model thereof

The invention provides a microbial marker and a prediction model for schizophrenia with social anxiety disorder. The microbial marker is a Bacteroides microorganism in saliva. The relevance between the relative abundance of Bacteroides microorganisms in saliva and social anxiety disorder is found for the first time. A Nomogram clinical prediction mode is formed by taking the specific microbial marker as a microbial marker in combination with a children bad experience scale and 6-hydroxymelatonin and 5-hydroxyindoleacetic acid in serum, so that objective biological indexes can be provided for early diagnosis and monitoring of whether schizophrenia is accompanied by social anxiety disorder or not; errors of subjective evaluation are reduced; moreover, the oral saliva sample has the obvious advantage of being easy to collect for psychiatric patients, the working difficulty of medical staff can be greatly reduced, and revolutionary changes of prediction, diagnosis and treatment of schizophrenia accompanied with social anxiety disorder are expected to be brought.
Owner:FUJIAN PROVINCIAL HOSPITAL

Effective treatment of depression in patients having impaired learning and / or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent

This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and / or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and / or memory or certain EEG characteristics.
Owner:ALTO NEUROSCIENCE INC

Combination therapy with cannabidiol and / or cobicistat

Compositions comprising cannabidiol and one or more compounds that are inhibitors of CYP2C19 and CYP3A4 enzymes are disclosed. Methods of using such compositions to treat pain, epilepsy, sleep deprivation, vomiting, nausea, psychosis, anxiety, depression, movement disorders, and other neuropsychiatric or neurogenic diseases are also provided. Compositions comprising cobicistat or a pharmaceutically acceptable isomer, salt, and / or solvate thereof; and at least one therapeutic agent metabolized by CYP2C19 and optionally CYP3A4 are provided. A method for inhibiting CYP2C19 and optionally CYP3A4 in a patient in need thereof is also provided, comprising administering to the patient an amount of cobicistat or a pharmaceutically acceptable isomer, salt, and / or solvate thereof effective to inhibit CYP2C19 and optionally CYP3A4 in the patient.
Owner:SHINKEI THERAPEUTICS INC

Modulators of g protein-coupled receptor 88

PendingUS20250367158A1Organic active ingredientsNervous disorderHuntingtons choreaAttention deficit hyperkinetic disorder
Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.
Owner:ACADIA PHARMACEUTICALS INC

A quantitative method for determining a mental state based on DRD1 and / or DRD5, and its application

A method for treating a mental disorder in a subject, comprising the step of normalizing the expression of both DRD1 and DRD5 belonging to the DRD1-like family of the subject to a preset standard level. The DRD1 / 5 level and expression can be increased or decreased bidirectionally by targeting the upstream promoter sequence of DRD1 / 5. The promoter activity of DRD1 / 5 can be attenuated by using antipsychotic drugs that directly target the DRD1 / 5 promoter. The antipsychotic drugs used are typical and / or atypical antipsychotic drugs such as haloperidol, risperidone, clozapine, and cariprazine. This treatment is also useful for subjects in whom the constitutive expression of the DRD1 / 5 gene is impaired. This method can be used to treat schizophrenia, autism, depression, mania, and bipolar disorder by normalizing the DRD1 / 5 expression level. The promoter gene sequencing of DRD1 and / or DRD5 can also be used for quantitative mental health screening by comparing with a standard sequence database.
Owner:シシャンドン

Pharmaceutical composition for improving bipolar depression and pharmaceutical preparation and application thereof

The invention discloses a pharmaceutical composition for improving biphasic depression and a pharmaceutical preparation and application thereof, and belongs to the technical field of research and development of biphasic depression drugs, the pharmaceutical composition is composed of nicotine and a second-generation antipsychotic drug, and the second-generation antipsychotic drug is quetiapine or risperidone. Experiments prove that the combined use of the nicotine and the second-generation antipsychotic has a synergistic effect in the aspect of improving the manic behavior of biphasic depression and has a better effect of improving the biphasic depression compared with the independent use of the nicotine and the second-generation antipsychotic.
Owner:BEIJING LIFE SCIENCE ACADEMY CO LTD

Therapeutic agent composition and method of use of combination therapy for treatment of mild cognitive impairment

The present invention recognizes that there is an unmet need for the treatment of mild cognitive impairment. A first aspect of the present invention generally relates to a method of treating, relieving, or alleviating mild cognitive impairment in a subject. A second aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease in a subject. A third aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease Psychosis in a subject. A fourth aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease behaviors, aggression, agitation, anger, apathy, or a combination thereof, in a subject. A fifth aspect of the present invention generally relates to a method of treating, relieving, or alleviating Early Onset Alzheimer's Disease in a subject.
Owner:TRAN LLOYD

Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease

The present invention generally relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogues and mimetics thereof, for treating, relieving, or alleviating Alsheimer's Disease, early onset Alzheimer's Disease, Alzheimer's Disease psychosis, or a combination thereof.
Owner:TRAN LLOYD HUNG LOI

Cancer patient psychological health prediction model based on multi-source data and application

The invention relates to a cancer patient mental health prediction model based on multi-source data and application. The model comprises the following steps: utilizing electronic health record (EHR) data and longitudinal data of cancer patients in prospective queue research; constructing and verifying a prediction model in combination with multiple factors; carrying out model training and verification by utilizing a machine learning algorithm so as to realize early prediction of anxiety, depression and psychotic disorders; and quantifying the contribution of each factor to the psychological health risk through model interpretive analysis. Through multi-source data fusion and an advanced algorithm, the early recognition rate of the psychological health problem of the cancer patient can be effectively improved, resource waste and diagnosis delay are reduced, and the treatment effect and life quality of the patient are improved.
Owner:JIANGYIN MOCHENG MEDICAL TECHNOLOGY CO LTD

Compositions for treating neurological disorders

Combination compositions of Compound 1 and fesoterodine for treating a neurological disorder (such as schizophrenia, Alzheimer's disease psychosis, Parkinson's Disease Psychosis, cognition in Alzheimer's disease, psychosis in dementia with Lewy bodies, bipolar disorders and dyskinesias) are described.
Owner:MAPLIGHT THERAPEUTICS INC

Automated diagnosis and treatment of mood and psychotic disorders using membrane protein clustering

PCT designated stageWO2025186790A8Image enhancementImage analysisBlood collectionMood
Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.
Owner:UVIC INDUSTRY PARTNERSHIPS INC

Method of treatment of schizophrenia

ActiveUS12544367B2Organic active ingredientsNervous disorderMetaboliteManagement of schizophrenia
The invention relates generally to improvements in the treatment of psychotic symptoms, and more particularly, to improvements in the identification of an individual or a population of individuals for whom treatment with iloperidone, an iloperidone metabolite, or pharmaceutically-acceptable salts thereof may provide a particular benefit in treating an individual's psychotic symptoms based on the individual's genotype at the PPEF2 locus.
Owner:VANDA PHARMACEUTICALS INC

Imidazole-containing fused ring derivative as well as preparation method and medical application thereof

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders

Compositions and methods for treating psychosis or a psychotic disorder with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, are provided. The compositions and methods may be used to improve one or more symptoms of psychosis or a psychotic disorder. Formula (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.
Owner:OVID THERAPEUTICS INC

Pyridine (pyrimidine) amine derivatives and their applications

The present invention relates to the field of chemical medicine, and provides a compound represented by Formula I, which acts on 5-HT 2A and 5-HT 2C receptors, and has a selectivity for 5-HT 2A superior to or similar to pimavanserin. It is used for the treatment of schizophrenia or behavioral disorders and psychosis related to Parkinson's disease and dementia. The antipsychotic activity of the compound of the present application is equivalent to that of pimavanserin, and its cardiotoxicity is less than that of pimavanserin.
Owner:NHWA PHARMA CORPORATION

Microbial marker for schizophrenia with social anxiety disorder and application thereof

The invention provides a microbial marker for schizophrenia with social anxiety disorder and application of the microbial marker. The microbial marker is a deinococcus microorganism in saliva. The relevance between the content of the deinococcus microorganisms in saliva and social anxiety disorder is found for the first time. Moreover, by taking deinococcus microorganisms in saliva as potential microbial markers, objective biological indexes can be provided for early diagnosis and monitoring of the schizophrenia accompanied with social anxiety disorder, and errors of subjective evaluation are reduced; moreover, compared with the intestinal specific biomarker, the oral saliva sample has the obvious advantages of easiness in collection and the like for psychotic patients, and the working difficulty of medical personnel can be greatly reduced; besides, the specific microbial marker can be combined with a traditional psychological scale and other biomarkers to form a more comprehensive diagnosis mode, and revolutionary changes of prediction, diagnosis and treatment of schizophrenia with social anxiety disorder are expected to be brought.
Owner:FUJIAN PROVINCIAL HOSPITAL

Modulators of g protein-coupled receptor 88

Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.
Owner:ACADIA PHARMACEUTICALS INC

Novel methods

The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
Owner:INTRA CELLULAR THERAPIES INC

Quantitative determination method for mental state based on DRD1 and / or DRD5 and application of quantitative determination method

A method of treating a psychiatric disorder in a subject comprises the step of normalizing the expression of DRD1 and DRD5 belonging to DRD1 class receptors in the subject to a preset standard level. By targeting an upstream promoter sequence of DRD1 / 5, the level and expression of DRD1 / 5 can be bidirectionally increased or decreased. The use of antipsychotic agents that directly target the DRD1 / 5 promoter can attenuate the DRD1 / 5 promoter activity. The antipsychotic agents used are typical and / or atypical antipsychotic agents, such as haloperidol, risperidone, clozapine and cariprazine. The treatment is also useful for subjects in which constitutive expression of the DRD1 / 5 gene is impaired. The methods can treat schizophrenia, autism, depression, mania, and bipolar affective disorders by normalizing DRD1 / 5 expression levels. Promoter gene sequencing of DRD1 and / or DRD5 can also be used for quantitative mental health screening by comparison to a standard sequence database.
Owner:施显东

Method for treating psychiatric disorders and dementia or mild cognitive impairment via intermittent memantine- and amantadine-based dosing regimen and drug combinations

PCT designated stageWO2026107197A2Amine active ingredientsDosing regimenLumateperone
Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.
Owner:THERACAST INC

Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders

Compositions and methods for treating psychosis or a psychotic disorder with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, are provided. The compositions and methods may be used to improve one or more symptoms of psychosis or a psychotic disorder.or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.
Owner:OVID THERAPEUTICS INC